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Recent studies have identified the liver X receptors
(LXR and LXR) as important regulators of cholesterol
and lipid metabolism. Although originally identified as
liver-enriched transcription factors, LXRs are also ex-
pressed in skeletal muscle, a tissue that accounts for
40% of human total body weight and is the major site of
glucose utilization and fatty acid oxidation. Neverthe-
less, no studies have yet addressed the functional role of
LXRs in muscle. In this work we utilize a combination of
in vivo and in vitro analysis to demonstrate that LXRs
can functionally regulate genes involved in cholesterol
metabolism in skeletal muscle. Furthermore we show
that treatment of muscle cells in vitro with synthetic
agonists of LXR increases the efflux of intracellular cho-
lesterol to extracellular acceptors such as high density
lipoprotein, thus identifying this tissue as a potential
important regulator of reverse cholesterol transport
and high density lipoprotein levels. Additionally we
demonstrate that LXR and a subset of LXR target genes
are induced during myogenesis, suggesting a role for
LXR-dependent signaling in the differentiation process.
Disorders of cholesterol and lipid metabolism are associated
with cardiovascular disease, obesity, diabetes, and hyperten-
sion. Not surprisingly organisms have developed exquisite reg-
ulatory networks that ensure lipid homeostasis is maintained
by controlling dietary intake, de novo synthesis, transport, and
catabolism. For instance, numerous studies over the past five
years have identified members of the nuclear hormone receptor
superfamily of ligand-dependent transcription factors as im-
portant regulators of the genes involved cholesterol and lipid
metabolism (3). In particular, the peroxisome proliferator-acti-
vated receptors (PPAR,1 /, and ), the farnesoid X receptor,
and the liver X receptors (LXR, and LXR) are transcription
factors whose activity can be controlled by the direct binding of
fatty acids (PPARs and LXRs) and cholesterol derivatives
(LXRs and farnesoid X receptor). Thus, these transcription
factors are poised to sense changes in the intracellular concen-
trations of lipids and cholesterol and to regulate cellular me-
tabolism accordingly (3, 4).
Recently several studies have demonstrated that the LXRs
play a dynamic role in the regulation of genes involved in
cholesterol and fatty acid metabolism. LXRs bind to DNA as
obligate heterodimers with retinoid X receptors and directly
bind cholesterol metabolites and fatty acids (5, 6). Interestingly
cholesterol derivatives and fatty acids have opposing effects on
LXR transcriptional activity. Oxysterols including 24(S), 25-
epoxycholesterol, 22(R)-hydroxycholesterol, and 24(S)-hy-
droxycholesterol are activators of LXR and increase transcrip-
tion of genes involved in sterol transport including the ATP
binding cassette transporters ABCA1, ABCG1, ABCG5, and
ABCG8 and the apolipoprotein apoE (7–11). The importance of
these LXR target genes to sterol metabolism has recently been
highlighted by linkage of ABCA1 to Tangier disease and
ABCG5 together with ABCG8 to sitosterolemia, both human
genetic syndromes characterized by perturbed cholesterol
transport (12–16). Strikingly, mutations in ABCA1 that give
rise to Tangier disease result in an almost complete absence of
HDL cholesterol and promote accumulation of cholesterol
within peripheral tissues. Biochemical analysis of ABCA1 in-
dicates that it mediates the transport of intracellular choles-
terol and phospholipids to extracellular acceptors such as HDL,
a process termed reverse cholesterol transport (17–19). LXR
agonists also increase expression of CYP7a, the gene encoding
cholesterol 7 hydroxylase, which is the rate-limiting enzyme
in the metabolic conversion of cholesterol to bile acids (20).
Thus, under conditions of elevated cholesterol, LXRs promote
the transfer of cholesterol from the periphery to the liver for
catabolism and excretion. Furthermore, up-regulation of
ABCA1, ABCG5, and ABCG8 in the intestine by LXRs limits
the absorption of sterols by promoting efflux from enterocytes
to the lumen, resulting in an overall decrease in cholesterol
loads (8).
Along with the effects on cholesterol metabolism, LXR ago-
nists also increase expression of genes involved in fatty acid
metabolism, including the master transcriptional regulator of
fatty acid synthesis, the sterol response element-binding pro-
tein 1c (SREBP1c) (1, 21, 22). Additionally, several of the genes
encoding the enzymes involved in fatty acid metabolism, in-
cluding fatty acid synthase (FAS) and stearoyl-CoA desaturase
1 (SCD-1), are regulated directly or indirectly by LXR (1, 20, 21,
23). The coordinate up-regulation of fatty acid synthesis with
* The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
¶ To whom correspondence should be addressed: X-Ceptor Therapeu-
tics, 4757 Nexus Centre Dr., San Diego, CA 92121. Tel.: 858-458-4542;
Fax: 858-458-4501; E-mail: ischulman@x-ceptor.com (to I. G. S.) or Uni-
versity of Queensland, Institute for Molecular Bioscience, Centre for
Molecular and Cellular Biology, Ritchie Research Laboratories, B402A,
St. Lucia, 4072, Queensland, Australia. Tel.: 61733654492; Fax:
61733654388; E-mail: g.muscat@imb.uq.edu.au (to G. E. O. M.).
1 The abbreviations used are: PPAR, peroxisome proliferator-acti-
vated receptor; LXR, liver X receptor; HDL, high density lipoprotein;
SREBP1c, sterol response element-binding protein 1c; FAS, fatty acid
synthase; SCD-1, stearoyl-CoA desaturase 1; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; DOTAP, N-[1-(2,3-dioleoyloxy)pro-
pyl]-N,N,N-trimethylammonium salts; DOSPER, 1-3-di-oleoyloxy-
2-(6-carboxy-spermyl)-propylamid.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 277, No. 43, Issue of October 25, pp. 40722–40728, 2002
© 2002 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org40722
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
reverse cholesterol transport is most likely to provide lipids for
the transport and storage of cholesterol. In contrast, however,
to the agonist activity of cholesterol metabolites, fatty acids act
as antagonists of LXR transcriptional activity, suggesting the
possibility of a negative feedback loop whereby the metabolic
end product inhibits the inducer (5).
Skeletal muscle accounts for40% of adult total body weight
and is a major site of glucose and fatty acid oxidation. Impor-
tantly, insulin regulates the balance between glucose and fatty
acid utilization in this tissue, and increased fatty acid oxidation
in skeletal muscle is a hallmark of type II diabetes. Although
LXRs have been shown to be important regulators of hepatic
fatty acid metabolism, the function of these transcription fac-
tors in muscle has not been well addressed. Nevertheless, given
the recent interest in LXR ligands as potential therapeutic
agents for the treatment of disorders of cholesterol and lipid
metabolism, the contribution of this major mass tissue to LXR
action must be defined. In this study we used in vivo analysis
in wild type and LXR knockout mice along with the well de-
fined C2C12 skeletal muscle cell culture model to characterize
LXR activity in muscle. The results of this work identify skel-
etal muscle as an important site of LXR activity.
EXPERIMENTAL PROCEDURES
In Vivo Analysis—Homozygous LXR-double knockout mice
(LXR/) were from a breeding colony established and maintained at
X-Ceptor Therapeutics Inc. Mice were fed ad libitum. The LXR agonist
T0901317 (1) was administered by daily oral gavage in a sesame oil/
ethanol vehicle via a 1-cc syringe fitted with a 20-gauge disposable
feeding needle for 7 days. Compound was solvated in ethanol (5% final
volume) and brought up to final volume with sesame oil (Sigma).
Plasma triglyceride levels were measured using an enzymatic assay
and the supplier’s protocols (Sigma).
Reporter Plasmids—Luciferase reporter plasmids were constructed
by PCR amplification of the human ABCA1 promoter (621–45) and
the mouse SREBP1c promoter (543–39) and cloning into pGL3-basic
(Promega, Madison, WI).
C2C12 Cell Culture and Transient Transfection Assays—Mouse myo-
genic C2 cells were grown in Dulbecco’s modified Eagle’s medium sup-
plemented with 20% fetal bovine serum in 5% CO2. Cells were induced
to biochemically and morphologically differentiate into multinucleated
myotubes by mitogen withdrawal (Dulbecco’s modified Eagle’s medium
supplemented with 2% horse serum) as previously described (2). Dif-
ferentiation was essentially complete within 96 h with respect to the
cytoskeletal and contractile isoform transition. For transient transfec-
tions, cells were grown in 24-well dishes to 60–70% confluence and
transfected with 0.5–0.8 g/well of the pGL3b-LUC, SREBP1c-LUC, or
ABC1c-LUC reporter constructs using a DOTAP/DOSPER (Roche Mo-
lecular Biochemicals) liposome mixture in 1 HEBS (42 mM HEPES,
275 mM NaCl, 10 mM KCl, 0.4 mM Na2HPO4, 11 mM dextrose, pH 7.1).
A -galactosidase expression plasmid was included as an internal con-
trol. The DNA/DOTAP/DOSPER mixture of 16–20 g of DNA supple-
mented with 60 l of DOTAP and 40 l of DOSPER in 200 l of 1
HEBS buffer was incubated for 10 min at room temperature and mixed
with 14.4 ml of fresh Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum or 2% horse serum. Subsequently, 0.6
ml/well of the DNA/DOTAP/DOSPER mixture was added to the cells
and incubated for 16–24 h. Post-transfection, the medium was replaced,
and the cells were grown a further 48 h. Cells were harvested and
assayed for luciferase activity. The luciferase activity in sample was
normalized by determining -galactosidase activity. Each experiment
represented at least two sets of independent triplicates to overcome the
variability inherent in transfection experiments.
RNA Isolation and Analysis of Gene Expression by Quantitative Re-
verse Transcription-PCR—Total RNA from mouse tissues and C2C12
cells was isolated using RNeasy kits (Qiagen Inc.) according to the
supplier’s total RNA isolation procedure. Real time PCR was performed
using a PerkinElmer/ABI 7700 prism. RNA samples were incubated
with 1 unit RNase-free DNase (Roche Molecular Biochemicals) per 1.6
g of total RNA for 40 min at 37 °C followed by a 10-min incubation at
75 °C. For each target quadruplicate reactions, each containing 100 ng
of total RNA (including one minus reverse transcriptase control), were
utilized. RNA was reverse-transcribed using 10 units of Superscript II
reverse transcriptase (Invitrogen), 400 nM target-specific reverse
primer, 500 M dNTPs, 10 mM dithiothreitol, and 1 Superscript II
buffer. Quantitative PCR of reverse transcriptase reactions was carried
out with 1.25 units of Taq polymerase (Invitrogen), 1 Taq buffer, 3 mM
MgCl2, 200 M dNTPs, 400 nM target-specific forward and reverse
primers, and 100 nM target-specific fluorogenic probe. All assays were
run for 40 cycles (95 °C for 12 s followed by 60 °C for 60 s). Probes and
primers were designed using Primer Express (Applied Biosystems,
Inc.). Levels of cyclophilin were measured in all in vivo samples, and the
results are presented as the number of target transcripts per cyclophilin
transcript. GAPDH was used to normalize transcript levels in the
experiments using C2C12 cells.
Cholesterol Efflux—C2C12 cells were differentiated as described
above for 48 h and then labeled with [14C]cholesterol for an additional
48 h. Labeled cells were washed, and efflux was initiated in medium
with or without 10 g/ml apoAI in the absence or presence of receptor-
specific ligands. After 24 h, media were removed, cell debris was pel-
leted, and radioactivity in the media was determined by scintillation
counting. To determine the cell-associated radioactivity, cells were ly-
sed in 0.2 M sodium hydroxide, and radioactivity was determine by
scintillation counting. Percent efflux was calculated by dividing the
radioactivity in the media by the sum of the radioactivity in the media
and cell lysate. ApoAI-dependent efflux was determined by subtracting
the efflux observed in the absence of added apoAI.
Statistical Analysis—Statistical analysis was carried out using a
two-tailed unpaired t test.
RESULTS
Regulation of LXR Target Genes in Muscle—Treatment of
rodents with synthetic LXR agonists has been shown to in-
crease expression of genes involved in cholesterol and lipid
metabolism in liver, intestine, and adipose tissue (1, 7–11, 21,
23). To examine the activity of LXR in skeletal muscle, we first
quantitated the mRNA levels of LXR and LXR in the quad-
riceps of mice and determined that LXR and LXR are ex-
pressed in skeletal muscle at similar levels (Fig. 1A). To further
define the functional activity of skeletal muscle LXR, wild type
and LXR/ mice were treated with the synthetic LXR ago-
nist T0901317 (1) for 7 days. After treatment, total RNA was
isolated from quadriceps, and LXR-dependent gene expression
was measured by quantitative real-time PCR. As shown in Fig.
1, B–F, treatment with LXR agonist increases the mRNAs
encoding known LXR target genes including ABCA1 (4.5-fold),
SREBP1c (8.3-fold), and apoE (2.3-fold). In contrast to what
has been observed in livers of treated mice (1, 8, 21), the
mRNAs encoding SCD-1 and FAS are not induced by LXR
agonist treatment in muscle. Nevertheless, SCD-1 and FAS are
significantly induced by LXR agonist treatment in the livers of
these same animals (Fig. 2). LXR agonist-dependent induction
of genes involved in fatty acid synthesis in the liver most likely
account for the increase plasma triglyceride levels observed in
agonist-treated mice (Fig. 2D). As expected, all agonist-depend-
ent effects on gene expression are completely eliminated in
LXR/ mice.
The results of Fig. 1 indicate that skeletal muscle is respon-
sive to LXR ligands. Studies in vivo, however, do not rule out
the possibility that effects on skeletal muscle gene expression
are indirect, arising from the ability of LXR agonists to influ-
ence cholesterol and lipid metabolism in other tissues. To con-
firm that LXR is active in skeletal muscle we turned to the well
established mouse C2C12 myoblast cell line as a model. Prolif-
erating C2C12 myoblasts can be induced to biochemically and
morphologically differentiate into post-mitotic multinucleated
myotubes by serum withdrawal in culture over a 96-h period.
This transition from a non-muscle phenotype to contractile
phenotype is associated with the repression of non-muscle pro-
teins and the activation of the contractile apparatus and met-
abolic enzymes. Treatment of differentiated myotubes (72 h
after serum withdrawal) with T0901317-induced expression of
LXR target genes involved in reverse cholesterol transport
including ABCA1, ABCG1, a second ABC transporter impli-
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cated in cholesterol transport, and apoE (Fig. 3, A–C). In
macrophages several studies have shown that ligands for
PPAR can also induce expression of ABCA1 indirectly via
up-regulation of the gene encoding LXR. Thus, at least in
macrophages, LXRs are thought to act downstream of PPAR
in a signaling cascade that leads to induction of ABCA1 and
increases in reverse cholesterol transport. In C2C12 cells, how-
ever, the PPAR ligand BRL49653 has little or no effect on the
expression of ABCA1 (Fig. 3A) or any other LXR target gene
examined (data not shown). Thus PPAR ligands do not act
directly on skeletal muscle to influence expression of genes that
regulate reverse cholesterol transport. Similarly, activators of
PPAR do not induce ABCA1 in C2C12 cells (data not shown).
LXR target genes that contribute to lipogenesis such as
SREBP1c, FAS, and SCD-1 were also induced by LXR agonist
in C2C12 cells (Fig. 2, D–F). As observed in vivo, however, the
induction of SREBP1c (8-fold) was much greater than the in-
duction observed for SCD-1 (1.5-fold) and FAS (3-fold).
Binding sites for LXR-retinoid X receptor heterodimers have
been identified in the promoters of the ABCA1 and SREBP1c,
and these genes have been shown to be direct targets of LXR in
the liver, intestine, and macrophages (1, 8, 21, 22). To evaluate
the ability of endogenous LXRs to directly activate SREBP1c
and ABCA1 in muscle, promoter-reporter constructs were
transfected into proliferating C2C12 myoblasts, and the cells
were allowed to differentiate in the absence or presence of LXR
agonist. As shown in Fig. 4, there is a dramatic ligand-depend-
ent induction of both promoters, indicating a direct action of
endogenous LXRs on SREBP1c and ABCA1 in muscle cells.
Regulation of Cholesterol Efflux in C2C12 Cells—ABCA1 has
been shown to be essential for the transfer of intracellular
cholesterol to extracellular acceptors such as HDL, a process
termed reverse cholesterol transport (17, 24, 25). The impor-
tance of ABCA1 to reverse cholesterol transport is illustrated
by the finding that inactivation of ABCA1 in humans results in
HDL deficiencies (17–19,25). Similarly, overexpression of
ABCA1 has been shown to elevate HDL by increasing reverse
cholesterol transport (26–28). To date, most studies of reverse
cholesterol transport have been carried out in fibroblasts and
macrophages. Nevertheless, given the ability of LXRs to regu-
late ABCA1 expression in muscle in vitro and in vivo, we
decided to measure reverse cholesterol transport in C2C12
cells. Treatment of [3H]cholesterol-labeled differentiated myo-
tubes with T0901317 resulted in a 2.9-fold increase in the
ability of these cells to efflux cholesterol to apoA1, and this
effect was further enhanced by an agonist for LXR’s het-
erodimeric partner retinoid X receptor (Fig. 5). Thus, skeletal
muscle is a potential site for reverse cholesterol transport and
may contribute to the control of HDL cholesterol levels. Once
again, the PPAR agonist BRL49653 had no effect.
Expression of LXRs during Myogenesis—Several studies
have shown that the gene encoding LXR is induced during the
FIG. 1. Expression of LXRs and LXR target genes in skeletal
muscle. LXR/ and LXR/ mice (n  4) were treated for 7 days
in the absence (white bars) or presence (black bars) of the LXR agonist
T0901317 (10 mg/kg), and total RNA was isolated from the quadriceps.
Expression of the mRNAs encoding LXR and LXR (A), ABCA1 (B),
apoE (C), SREBP1c (D), SCD-1 (E), and FAS (F) was determined by
real-time quantitative PCR. Levels of cyclophilin were measured in all
samples, and the results are presented as the number of target tran-
scripts per cyclophilin transcript. RNA from each individual animal was
assayed in quadruplicate. p values indicate statistically significant
differences between vehicle and T0901317-treated animals.
FIG. 2. LXR agonist-dependent induction of SCD-1 and FAS in
the liver. LXR/ and LXR/ mice (n  4, the same mice used in
Fig. 1) were treated for 7 days in the absence (white bars) or presence
(black bars) of the LXR agonist T0901317 (10 mg/kg), and total RNA
was isolated from the liver. Expression of the mRNAs encoding
SREBP1c (A), SCD-1 (B), and FAS (C) was determined by real-time
quantitative PCR. Levels of cyclophilin were measured in all samples,
and the results are presented as the number of target transcripts per
cyclophilin transcript. RNA from each individual animal was assayed in
quadruplicate. Plasma triglyceride levels (D) were determined as de-
scribed under “Experimental Procedures.” p values indicate statisti-
cally significant differences between vehicle- and T0901317-treated
animals.
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differentiation of monocytes to macrophages, indicating an im-
portant role for this receptor in macrophage biology (29–31). To
examine LXR activity during skeletal myogenesis, expression
levels of LXR and LXR were measured in differentiating
C2C12 cells (Fig. 6). LXR is induced beginning when cells
reach confluence (Fig. 6A, CMB) and peaking as myoblasts exit
the cell cycle and form differentiated multinucleated cells (Fig.
6A, MT1), suggesting a role for this isotype in the myogenic
process. In contrast, LXR mRNA is constitutively expressed
during myogenic differentiation in culture and is 200-fold more
abundant than LXR in proliferating myoblasts (Fig. 6B).
Northern analysis demonstrates the induction of myogenin
mRNA (encoding the basic HLH protein), repression of the
cytoskeletal non-muscle /-actin mRNAs, and the activation
of the sarcomeric -actins relative to equivalent levels of
GAPDH mRNA, confirming that these cells had terminally
differentiated (Fig. 6C).
Analysis of LXR targets during myogenesis indicates that
genes involved in reverse cholesterol transport (ABCA1,
ABCG1, and apoE) are also induced from 4.7- to 29-fold (Fig. 7,
A–C) during the differentiation process in the absence of added
exogenous LXR ligands. The kinetics of the ABCA1, ABCG1,
and apoE lag slightly behind the induction of LXR and, thus,
are consistent with the hypothesis that LXR plays a role in
inducing these genes. The LXR targets involved in lipogenesis
(SREBP1c, SCD-1, and FAS), however, are poorly, if at all,
induced during differentiation (Fig. 7, D–F). This observation is
particularly interesting for SREBP1c and FAS, which have
recently been shown to be directly regulated by LXR (1, 21,
23). Nevertheless, treatment of differentiating C2C12 cells
FIG. 3. Regulation of LXR target genes in C2C12 cells. Confluent
C2C12 cells were allowed to differentiate into myotubes in the absence
of serum for 72 h. After differentiation cells were cultured for an
additional 24 h in the absence (white bars) or presence of 1.0 M LXR
agonist T0901317 (black bars) or 5.0 M of the PPAR agonist
BRL49653 (striped bar, A only), and total RNA was isolated. Expression
of the mRNAs encoding ABCA1 (A), ABCG1 (B), apoE (C), SREBP1c
(D), SCD-1 (E), and FAS (F) was determined by real-time quantitative
PCR. Levels of GAPDH were measured in all samples, and the results
are presented as the number of target transcripts per GAPDH tran-
script. Fold inductions by T0901317 relative to vehicle-treated controls
are noted above the appropriate bars (p  .02). Each sample was
assayed in quadruplicate.
FIG. 4. Induction of the ABCA1 and SREBP1c promoters by
endogenous LXRs in C2C12 cells. Reporter constructs with the
human (h) ABCA1 (A) and mouse (m) SREBP1c (B) promoters linked to
luciferase were transfected into proliferating C2C12 myoblasts along
with -galactosidase expression plasmid. Transfected cells were then
allowed to differentiate for 48 h in the absence (white bars) or presence
(black bars) of 1.0 M T0901317. After ligand treatment, luciferase
activity was measured and normalized by -galactosidase activity. Each
sample was assayed in triplicate.
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with LXR ligands increases the mRNAs for all LXR target
genes examined including SREBP1c, SCD-1, and FAS (Fig. 2
and data not shown), indicating that endogenous LXRs are
competent to activate these targets during myogenesis if a
potent agonist is available. These observations suggest, at least
during myogenesis, that the regulation of these two functional
classes of LXR targets (cholesterol transport and fatty acid
synthesis) can be temporally and mechanistically separated.
DISCUSSION
In this study we demonstrate that both LXR and LXR are
expressed in skeletal muscle and can be functionally regulated
by LXR agonists. The ability of LXRs to induce reverse choles-
terol transport in skeletal muscle, most likely via the up-regu-
lation of ABCA1, ABCG1, and apoE expression, suggests that
this major mass tissue can make significant contributions to
whole body cholesterol homeostasis. We have not detected LXR
agonist-dependent effects on the expression of 3-hydroxy-3-
methylglutaryl-CoA reductase in muscle, indicating that in-
creased reverse cholesterol transport is not stimulating de novo
cholesterol synthesis (data not shown). Not surprisingly, the
ability of LXR agonists to promote reverse cholesterol transport
has stimulated great interest in the potential of small molecule
activators of LXRs as therapeutic agents for the treatment of
cardiovascular disease (3, 4). Previous studies, however, focus
on the therapeutic benefit of regulating reverse cholesterol
FIG. 6. LXR is induced during myogenesis. Total RNA was
isolated from proliferating C2C12 myoblasts (PMB), confluent myo-
blasts (CMB), or cells that had been differentiated to myotubes in the
absence of serum for 24 (MT1) and 96 (MT4) h. The expression levels of
LXR (A) and LXR (B) were determined by real-time quantitative
PCR. Levels of GAPDH were measured in all samples, and the results
are presented as the number of target transcripts per GAPDH tran-
script. Each sample was assayed in quadruplicate. The fold induction of
LXR mRNA when MT1 is compared with PMB is noted over the
appropriate bar (p .01). C, Northern analysis was used to measure the
levels of the mRNAs encoding myogenin, sarcomeric, and cytoskeletal
actins and GAPDH. All samples were run on the same blot. An irrele-
vant lane (between lanes 3 and 4) was removed for preparation of the
figure.
FIG. 7. Expression of LXR target genes during myogenesis.
Total RNA was isolated from proliferating C2C12 myoblasts (PMB),
confluent myoblasts (CMB), or cells that had been differentiated to
myotubes in the absence of serum for 24 (MT1) and 96 (MT4) h. The
expression levels of ABCA1 (A), ABCG1 (B), apoE (C), SREBP1c (D),
SCD-1 (E), and FAS (F) were determined by real-time quantitative
PCR. Levels of GAPDH were measured in all samples, and the results
are presented as number of target transcripts per GAPDH transcript.
Significant fold inductions (p  .02) when compared with PMB levels
are noted over the relevant bars. Each sample was assayed in
quadruplicate.
FIG. 5. Induction of reverse cholesterol transport in differen-
tiated myotubes by LXR. Confluent C2C12 cells were allowed to
differentiate into myotubes in the absence of serum for 72 h. After
differentiation, cells were cultured for an additional 24 h in the absence
(white bar) or presence of 1.0 M LXR agonist T0901317 (black bar), 1.0
M of the retinoid X receptor (RXR) agonist LG101305 (spotted bar), 1.0
M T0901317  1.0 M LG101305 (gray bar), or 5.0 M of BRL49653
(striped bar). After ligand treatment, ApoA1-dependent cholesterol ef-
flux was measured as described under “Experimental Procedures.”
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transport in macrophage foam cells, a cell-type that directly
contributes to atherosclerotic lesion development (32). Based
on the overall mass of skeletal muscle, our work also identifies
this tissue as an important site of action for LXR-based drugs.
LXRs also regulate fatty acid metabolism by controlling ex-
pression of SREBP1c, the master transcriptional regulator of
fatty acid synthesis, and the enzymes that participate in this
metabolic pathway (1, 21, 22). Not surprisingly, treatment of
experimental animals with LXR agonists results in significant
increases in hepatic and serum triglycerides (1). The ability of
LXRs to regulate fatty acid metabolism in skeletal muscle has
important consequences for carbohydrate and lipid homeosta-
sis. In response to insulin, skeletal muscle accounts for the
majority of glucose uptake in the body. Insulin also induces
SREBP1c expression in skeletal muscle, and this regulation is
defective in patients with type II diabetes (33). Thus LXR
ligands should partially mimic insulin by inducing SREBP1c in
muscle and may function as insulin sensitizers. However, sig-
nificant correlations also exist between high levels of intra-
muscular lipid content and insulin resistance (34, 35), suggest-
ing that increased fatty acid synthesis by muscle may also have
adverse effects. Interestingly, although SREBP1c is induced in
skeletal muscle by LXR ligands, two down-stream targets in-
volved in fatty acid synthesis, SCD-1 and FAS, are not. Thus, in
muscle LXR activity may be uncoupled from fatty acid metab-
olism. Clearly additional studies will be needed to fully under-
stand the cross-talk between insulin signaling and LXR tran-
scriptional activity.
The accumulation of cholesterol by macrophages in the arte-
rial wall via the uptake of oxidized LDL particles is one the first
steps in the development of atherosclerosis (32). Not surpris-
ingly, the ability of LXR to regulate reverse cholesterol trans-
port in macrophages, i.e. the efflux of intracellular cholesterol
to extracellular HDL particles, has stimulated great interest in
understanding how LXR activity is regulated. In macrophages
a second member of the nuclear receptor superfamily, PPAR,
directly regulates the gene encoding LXR (36, 37). Interest-
ingly, agonists of PPAR increase reverse cholesterol transport
in isolated macrophages (10, 37) and decrease atherosclerosis
in rodent models (38). Based upon these observations and the
ability of LXR to directly regulate ABCA1, it has been sug-
gested that induction of LXR accounts at least in part for the
ability of PPAR agonists to stimulate reverse cholesterol
transport (3, 4). In muscle, however, PPAR is expressed at
relatively low levels, and in differentiated C2C12 myotubes a
potent synthetic PPAR agonist does not induce expression of
ABCA1 or increase reverse cholesterol transport. Thus when
compared with PPAR ligands, activators of LXR may have the
added benefit of stimulating reverse cholesterol transport in a
cell type that accounts for 40% of human total body weight.
Taking advantage of the C2C12 cell culture system we dem-
onstrate that the mRNA encoding LXR is induced during
skeletal myogenesis just before the induction of LXR target
genes involved in reverse cholesterol transport (ABCA1,
ABCG1, and apoE). Strikingly, however, LXR targets involved
in fatty acid synthesis (SREBP1c, FAS, and SCD-1) are not
coordinately regulated with LXR. These observations support
the hypothesis that there are inherent differences in the regu-
lation of these two classes of LXR targets. This apparent di-
chotomy in the LXR-dependent regulation of genes involved in
reverse cholesterol transport and fatty acid metabolism has
important implications for the development of LXR agonists as
therapeutic agents. Increasing expression of ABC transporters
and apoE with LXR agonists has several beneficial effects
including increasing reverse cholesterol transport, elevating
HDL cholesterol levels, and limiting the absorption of dietary
cholesterol (7–10). In contrast, the LXR-dependent hypertri-
glyceridemia induced at least in part by up-regulation of fatty
acid synthesis is an undesirable side effect (1). The differential
induction of these two classes of LXR target genes observed in
skeletal muscle and during myogenesis, however, suggests that
there are mechanistic differences in the regulation of each
target class that can be exploited for drug development. Future
studies that define the mechanistic basis for this differential
regulation will contribute to an understanding of biological
function of LXR and assist in the development of effective
LXR-based therapeutic agents.
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